Elsevier

Maturitas

Volume 22, Issue 3, November 1995, Pages 255-262
Maturitas

Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy

https://doi.org/10.1016/0378-5122(95)00935-EGet rights and content

Abstract

Objectives: To compare immunohistochemical localization of insulin-like growth factor binding protein-1 (IGFBP-1) in endometrial stromal cells with endometrial morphology during three regimens of continuous combined hormone replacement therapy. Methods: Endometrial samples for morphological examination and immunohistochemical staining with monoclonal antibody against IGFBP-1 were obtained from 30 menopausal women before treatment and after 12 and 24 months of continuous combined hormone replacement therapy. All women received percutaneous estradiolgel releasing 1.5 mg estradiol daily. Regarding progestins, patients were divided into three groups: one group (n = 15) had a 20 μg/24 h levonorgestrel-releasing intrauterine device (LNG-IUD); the women in the other two groups received micronised natural progesterone either 100 mg orally (n = 7) or 100–200 mg vaginally (n = 8) daily, 25 days per calendar month. Results: Before treatment the endometrium of all women was atrophic or subatrophic and no IGFBP-1 could be detected in any of the samples which contained enough stromal cells for evaluation. After 12 and 24 months of treatment, epithelial atrophy with decidual transformation in stroma was detected in all specimens in the LNG-IUD group, and IGFBP-1 was localized in decidualized stromal cells in all samples. In the other two groups, no signs of progestin effect were detected by microscopic examination in any of the endometrial samples and IGFBP-1 staining was completely negative in all of them. Conclusion: A striking difference occurred in both morphological and biochemical response in the endometrium of women treated with LNG-IUD compared with those receiving oral or vaginal micronised progesteron during continuous combined HRT. Micronised progesterone at doses used in this study turned out to be ineffective to prevent the proliferative effect of estrogen. Immunohistochemical localization of IGFBP-1 in endometrial stromal cells strongly correlated with decidual reaction in all endometrial specimens exposed to LNG-IUD, suggesting that the immunostaining of IGFBP-1 can be used as a means of assessing the strength of progestin effect in the endometrium during HRT.

References (21)

There are more references available in the full text version of this article.

Cited by (35)

  • The role of androgens and the androgen receptor in cycling endometrium

    2012, Molecular and Cellular Endocrinology
    Citation Excerpt :

    PCOS affects between 4% and 23% of women, where ovarian hyperandrogenaemia is the most consistent endocrine feature (Sulcova et al., 1997). Interestingly, ovarian theca cells of women with PCOS constitutively secrete increased amounts of androgens, through elevated intrinsic activity of P450c17, 17βHSD and 3βHSD enzymes (Suvanto-Luukkonen et al., 1995). Therefore, the ovaries serve as the primary contributor to hyperandrogenaemia.

  • Current issues in the management of endometrial cancer

    2008, Mayo Clinic Proceedings
    Citation Excerpt :

    Obesity remains a risk factor for EC even when circulating concentrations of estrogen are normal, perhaps because of a reduction in sex hormone-binding globulins and the resultant increase in bioavailable estrogen.6 Estrogen receptor transcriptional activity can also be induced by insulinlike growth factor 1 in the absence of estradiol, providing evidence of cross-talk between these pathways.10–14 Physical inactivity, high caloric intake, blood pressure above 140/90 mm Hg, and high serum glucose concentrations are additional BMI-independent risk factors.9,15–18

  • Endometrial cancer

    2005, Lancet
    Citation Excerpt :

    The use of an intrauterine device and tubal ligation have also been associated with a lower risk.74,75 Whether a levonorgestrel-containing intrauterine device further protects is unclear.51 Contraceptive pills containing oestrogens and progestagens lower the endometrial-cancer risk.76

View all citing articles on Scopus
View full text